Ryan Barbara 4

What Happened

• Ryan Barbara, a director of Indivior Pharmaceuticals, acquired 8 shares in an open‑market/private purchase on 2026-03-13 at $31.09 per share, for a total cost of approximately $249. This was a purchase (insider buy), which some investors view as a modestly bullish signal.

Key Details

• Transaction date: 2026-03-13
• Transaction type/code: Purchase (P) — open market or private purchase
• Price and amount: 8 shares at $31.09 each; total ≈ $249
• Shares owned after transaction: Not specified in the provided filing data
• Footnotes/plan details: No 10b5‑1 plan, tax withholding, or other footnotes provided in the supplied information
• Filing timeliness: Reported with the same period date (2026-03-13); appears to be timely based on available data

Context

• Small dollar purchases like this are routine and may reflect personal allocation rather than a strong endorsement; they are factual data points rather than proof of future company performance.
• For retail investors, aggregated patterns of insider buying across multiple insiders or larger transactions are typically more informative than single, small purchases.